Psoriasis Treatment Market By Treatment Type (Systemic Treatments {Biologics, Oral Medication [Methotrexate, Cyclosporine, Acitretin]}, Topical Treatments {Corticosteroids, Vitamin D Analogs, Retinoids, Calcineurin Inhibitors}, Phototherapy {UVB Therapy, PUVA (Psoralen + UVA), Excimer Laser}), By Disease Severity (Mild, Moderate, Severe), By Route of Administration (Topical, Oral, Injectable, Intravenous), and By Distribution Channel (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Psoriasis Treatment market accounted for USD 24.3 Billion in 2024 and is expected to reach USD 55.5 Billion by 2035, growing at a CAGR of around 7.8% between 2025 and 2035. The psoriasis treatment market encompasses a variety of medicines used to treat psoriasis, a skin-related condition that impairs an individual's skin functionality and immunity. This market involves topical agents, oral medication, and biological agents that act at certain steps in the immune response. This has been attributed to the gradual emergence of new medicines that increase the efficacy and quality of their effects on patients. Furthermore, the sector is being propelled by improved awareness, the rising prevalence of psoriasis, and research into new therapies. A wide product portfolio and rising R&D investment in dermatological products point to high growth potential in the psoriasis treatment market.

Report Scope:

Market Dynamics

Innovative biologic therapies provide targeted and effective treatment options.

The psoriasis treatment market is driven by the increasing incidence rate of the skin condition, people’s awareness of this disease and the corresponding treatment, and biologic therapy. Because many people suffer from psoriasis, there has been increased pressure for effective and selective therapy, leading to the development of immunologically targeted pathways. Similarly, scientific innovation and the expansion of clinical trials contribute to a better understanding of diseases and encourage the discovery of new treatments. Special emphasis is placed on the fact that we are currently witnessing a transition toward more personalized treatment. Furthermore, greater funding for dermatological research is projected to spur the discovery of new treatments, boosting market volatility. This demand, innovation, and awareness factor is driving growth in the psoriasis treatment market.

Rising prevalence of psoriasis globally increases demand for treatments.

The increased rates of psoriasis across the world significantly drive treatment demand. Its prevalence has risen due to a better understanding of the disease, improved diagnostic procedures, and the availability of new treatment options. Psoriasis incidence is thought to be impacted by human habits, events, and physical surroundings. The National Psoriasis Foundation undertook a study to establish the prevalence of the illness. Psoriasis affects about 8 million people in the United States. Furthermore, the increase in adaptation in research and development has resulted in the introduction of new biologics and other targeted medicines to improve patient outcomes. This is increasing the number of instances and inventions, resulting in a competitive market for psoriasis therapy around the world. The aging population and rising healthcare expenditures all contribute to increased demand, as people become more prone to skin diseases such as psoriasis as they age.

Economic downturns reduce healthcare spending, impacting treatment market growth.

The key restriction to the psoriasis treatment market is an economic downturn, which reduces healthcare spending. Consumers and healthcare providers may ignore important interventions, and psoriasis therapies tend to decline. The high cost of the more progressive biologic treatment regimen may also be a barrier to patient acquisition, especially among the populace with low purchasing power. Inadequate insurance and multiple policies on reimbursement make it hard for patients to pay for the required drugs. The emphasis on economical treatment is viewed as a method for diverting attention away from new and potentially more effective treatments.

Exacerbating challenges, patients eventually abandon their prescription schedules and treatment regimens, resulting in severe symptoms and side effects, prompting them to discontinue their medications. Furthermore, the availability of self-care items may provide patients with cheaper alternatives, reducing market growth. Onerous regulations on drug approval and a saturated market with many generic products can raise competition, adversely affecting the chance of the new treatment options establishing themselves. Altogether, these considerations generate an unfavorable climate for the constant market growth for psoriasis treatment.

Combination therapies can provide improved outcomes for patients effectively.

The psoriasis treatment market offers opportunities because the target disease is becoming more prevalent and patients require better medications. New trends for the treatment of SPI include combination therapies, which involve combining treatment modalities to increase effectiveness and reduce complications. The former analog can contribute to increased effectiveness because this approach acts from different angles to the disease. The increases in the availability of biologics and innovative therapy have only served to accelerate this process, presenting more possibilities for individualized therapy programs. With a larger emphasis on the patient's concerns, one could argue that new mixed conditions will emerge sooner or later. These conditions will be based on existing data and supported by a variety of scientific research activities, including clinical trials. This trend means that pharmaceutical companies can provide a comprehensive bundle of psoriasis treatments that better serve patients' different demands. As healthcare providers seek integrated solutions, the industry has a significant potential for long-term growth and diversification.

Development of personalized medicine improves efficacy and patient satisfaction.

The trends in psoriasis treatment open up a wide range of options in personalized medicine. Genetic, environmental, and lifestyle information gives doctors an advantage when selecting specific treatment plans to offer patients treatment that effectively cures and satisfies their expectations. This approach underpins the ability to identify specific biomarkers that determine the effectiveness of particular therapies, eliminating the guesswork involved in prescription. Further, customized treatment regimens are likely to be more effective since patients will be more willing to follow certain courses of treatment. Disparities in psoriasis have resulted in the scaled creation of targeted therapeutics, broadening the pharmaceutical market share through the use of precision medicine. Because of increased patient awareness and specialized expectations, the market is likely to rise significantly.

Industry Experts Opinion

"Advanced therapies represent an important option in the treatment of plaque psoriasis, but as a physician, it's critically important to continually assess if patients are having an optimal response to treatment, as residual psoriasis can still have a significant impact on a patient's life. This study showed that risankizumab was able to improve clinical signs and symptoms of patients who had a suboptimal response with the anti-IL-17 therapies secukinumab and ixekizumab, contributing to the whole of evidence supporting risankizumab use in moderate to severe plaque psoriasis."

• Professor Richard Warren from the University of Manchester and Norten Care Alliance, UK.

“The robust data seen in the OPT Pivotal studies presented at this meeting provide important information on the profile of oral tofacitinib for moderate to severe psoriasis, and underscore that if approved, tofacitinib may offer a clinically meaningful option in oral therapy as the first potential treatment in a new class of medicines for this chronic condition,”

• Kim A. Papp, MD, PhD, FRCPC, Probity Medical Research.

Segment Analysis

Based on the treatment type, the Psoriasis Treatment Market is classified into Systemic Treatments, Topical Treatments, and Phototherapy. In the Psoriasis Treatment Market, the Systemic Treatments category is the largest. These treatments take the form of biologics and oral medications, which target the immune system that causes psoriasis and are hence superior to topical remedies. Its effectiveness in treating moderate to severe psoriasis and enhancing patients' quality of life has resulted in increased access for practitioners and patients. Furthermore, the continuous advancement of biologic medicines supports their use as a priority in the long-term control of the disease.

Based on the route of administration, the Psoriasis Treatment Market is classified into Topical, Oral, Injectable, and Intravenous. The injectable segment has the largest market share in the psoriasis treatment market due to rising cases of moderate to severe psoriasis and the effectiveness of biologic therapy. Injected biologic agents, monoclonal antibodies, and other targeted drugs create positive changes in skin lesions and the patient's quality of life. They are preferred above other treatments because of their ability to selectively target immunological pathways that cause psoriasis. This trend is anticipated to continue as better therapies are produced to improve the care of persons suffering from this chronic illness.

Regional Analysis

The psoriasis treatment market in North America is relatively fragmented due to the availability of many treatment options as psoriasis prevalence and skin health awareness rise. Some of the stakeholders involved are manufacturers of biologic and systemic therapies and topical therapeutic drugs. The healthcare industry in the region has advanced and dedicated significant resources to research, resulting in more treatment alternatives. Further, increasing patient self-organization and shared supportive initiatives provide additional opportunities to access the required treatment. Telemedicine and advanced digital health solutions enhance patient engagement and psoriasis condition management. However, factors that may hinder market growth include expensive treatment services and the level of insurance provision. The situation and market for their treatment in North America are expected to improve as the techniques' efficacy and safety improve.

The psoriasis treatment market in Europe is influenced by healthcare systems, patient demographics, and treatment options. Due to their high healthcare costs and availability of cutting-edge treatments, Northern European countries frequently select sophisticated biologics and new therapeutics as critical therapeutic options. The value of traditional therapies is higher among the countries of Southern Europe because of the differences in the healthcare sector’s expenses and options available in the area. Regulations are also changing, with innovative treatments being introduced in some nations faster than others. Further, a growing rate of incidences of psoriasis and enhanced awareness among healthcare professionals are fueling the market’s progression across the continent. Pharmaceutical companies and healthcare professionals need to work in partnership to solve problems and improve the quality of life for patients.

Competitive Landscape

The psoriasis treatment market is highly saturated, with significant pharma corporations and biotech startups. Key players such as AbbVie, Amgen, Johnson & Johnson, and Novartis hold new and effective biologics, including Humira, Enbrel, and Cosentyx. There are more recent additions, such as Skyrizi from AbbVie, which has demonstrated efficacy in clinical trials of moderate to severe psoriasis. Bristol-Myers Squibb’s Sotyktu has received some attention for having a precise mechanism of action, which is a trend for personalized therapy. The company turned Taltz and Olumiant into an even bigger market, focusing on efficacy and safety. Market demand is rising for oral treatment options as Pfizer’s Xeljanz is now getting more recognition. There is a shift toward patient requirements and individual care, with target treatment packages and the additional value of linked therapies. Further, as research advances, new entrants, innovations, and improved economics in biologics and systemic medicines will continue to change the competitive structure of the market in quest of a competitive edge.

Psoriasis Treatment Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In May 2024, Innovent Biologics announced the successful Phase III study of IBI306 in the treatment of psoriasis. In terms of efficacy, the study found that patients had higher scores for psoriasis symptoms when compared to a placebo. Such findings suggest IBI306 as a potential new treatment for patients with moderate to severe psoriasis.  
• In October 2023, BIMZELX (bimekizumab), UCB's medication for treating individuals with moderate to severe psoriasis, will be available. Clinical assessments reveal that BIMZELX significantly lowers psoriasis when compared to other drugs, leading to this approval.
• In March 2023, AbbVie announced late-breaking results from a study that evaluated the 52-week efficacy and safety of SKYRIZI® (risankizumab) in plaque psoriasis patients who had previously experienced suboptimal responses to IL-17 inhibitors. The findings highlighted SKYRIZI's potential as an effective treatment alternative for this group.

Report Coverage:

By Treatment Type

• Systemic Treatments
  • Biologics
  • Oral Medication
    • Methotrexate
    • Cyclosporine
    • Acitretin
• Topical Treatments
  • Corticosteroids
  • Vitamin D Analogs
  • Retinoids
  • Calcineurin Inhibitors
• Phototherapy
  • UVB Therapy
  • PUVA (Psoralen + UVA)
  • Excimer Laser

By Disease Severity

• Mild
• Moderate
• Severe

By Route of Administration

• Topical
• Oral
• Injectable
• Intravenous

By Distribution Channel

• Hospitals
• Specialty Clinics
• Retail Pharmacies
• Online Pharmacies

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• AbbVie
• Amgen
• Johnson & Johnson
• Novartis
• Pfizer
• Bristol-Myers Squibb
• Eli Lilly
• GSK
• Dermira
• Incyte
• Sanofi
• Celgene
• AstraZeneca
• UCB
• Mylan

Frequently Asked Questions (FAQs)